NLRP3 and atherosclerosis: The pharmacological inhibition of NLRP3 inflammasome activation by MCC950 has therapeutic efficacy against various preclinical immunopathological models, such as cryopyrin-associated autoinflammatory syndrome (CAPS), experimental autoimmune encephalomyelitis (EAE) [98], Alzheimer’s disease [106], Parkinson’s disease [109], traumatic brain injury [110], atherosclerosis [111], diabetes [112], steatohepatitis [113] and colitis [114].